Table 1 Baseline patient characteristics
EZ + Simva 10/20 mg (N = 37) | Simva 40 mg (N = 50) | Between treatment difference | |
|---|---|---|---|
Demographics | |||
Age, mean years (SD) | 65 (6.5) | 64 (6.1) | p = 0.204 |
Females, n (%) | 16 (43.2) | 12 (24.0) | p = 0.078 |
Body mass index, kg/m2, mean (SD) | 28.9 (4.1) | 28.4 (3.6) | p = 0.584 |
Hypertension, n (%) | 30 (81.1) | 32 (62.0) | p = 0.090 |
Baseline lab values, mean (SD) | |||
Low-density lipoprotein cholesterol, mmol/L | 3.3 (0.5) | 3.2 (0.5) | p = 0.413 |
Total cholesterol, mmol/L | 5.2 (0.6) | 5.1 (0.6) | p = 0.335 |
High-density lipoprotein cholesterol, mmol/L | 1.2 (0.3) | 1.1 (0.3) | p = 0.202 |
Triglycerides, mmol/L | 1.6 (0.7) | 1.6 (0.7) | p = 0.933 |
Fasting plasma glucose, mmol/L | 10.2 (2.7) | 10.0 (2.9) | p = 0.717 |
Hemoglobin A1c | 7.5 (0.7) | 7.4 (0.8) | p = 0.539 |
Aspartate aminotransferase, U/L | 16.9 (3.4) | 20.2 (5.1) | p = 0.001 |
Alanine aminotransferase, U/L | 20.8 (7.1) | 27.6 (11.4) | p = 0.002 |
Creatine kinase, U/L | 80.4 (35.5) | 107.5 (47.3) | p = 0.002 |
Prevalence of cardiovascular diseases, n (%) | |||
Cerebrovascular disease | 3 (8.1) | 5 (10.0) | p = 1.000 |
Peripheral vascular disease | 7 (18.9) | 11 (22.0) | p = 0.999 |
Ischemic heart disease | 22 (59.5) | 27 (54.0) | p = 0.666 |
Cerebrovascular disease + PAD | 1 (2.7) | 2 (4.0) | p = 1.000 |
Cerebrovascular disease + ischemic heart disease | 0 (0.0) | 0 (0.0) | -- |
PAD + ischemic heart disease | 3 (8.1) | 4 (8.0) | p = 1.000 |
Cerebrovascular disease + PAD + ischemic heart disease | 1 (2.7) | 1 (2.0) | p = 1.000 |